Research in Social and Administrative Pharmacy
Volume 7, Issue 1 , Pages 64-80 , March 2011

Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents

  • Yann Ferrand, M.S.

      Affiliations

    • College of Business, University of Cincinnati, Cincinnati, OH 45221-0195, USA
    • ,
  • Christina M.L. Kelton, Ph.D.

      Affiliations

    • College of Business, University of Cincinnati, Cincinnati, OH 45221-0195, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 513 556 2983; fax: +1 513 556 2953.
    • ,
  • Jeff J. Guo, Ph.D.

      Affiliations

    • College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA
    • ,
  • Martin S. Levy, Ph.D.

      Affiliations

    • College of Business, University of Cincinnati, Cincinnati, OH 45221-0195, USA
    • ,
  • Yan Yu, Ph.D.

      Affiliations

    • College of Business, University of Cincinnati, Cincinnati, OH 45221-0195, USA

References 

  1. Huszonek JJ, Dewan MJ, Koss M, Hardoby WJ, Ispahani A. Antidepressant side effects and physician prescribing patterns. Ann Clin Psychiatry. 1993;5:7–11
  2. Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA. 1998;279:526–531
  3. Adelmann PK. Mental and substance use disorders among Medicaid recipients: prevalence estimates from two national surveys. Adm Policy Ment Health. 2003;31(2):111–129
  4. IMS Health. Top-line industry data. 2008 U.S. sales and prescription information. Available at, http://www.imshealth.com. Accessed 15-07-09.
  5. Barry CL, Thomas MR. Improving the quality of depression care in Medicaid. Psychiatr Serv. 2005;56:1193–1195
  6. Katon W, Sullivan M, Walker E. Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Ann Intern Med. 2001;134:917–925
  7. Kendrick T. Primary care options to prevent mental illness. Ann Med. 1999;31:359–363
  8. Chen Y, Kelton CML, Jing YH, Li X, Guo JJ. Trend analyses of utilization, price, and spending for antidepressant drugs in the US Medicaid program. J Res Soc Adm Pharm. 2008;4:244–257
  9. National Pharmaceutical Council, Inc. Pharmaceutical Benefits Under State Medical Assistance Programs, 2004. Reston, VA, 2005.
  10. Bureau of Labor Statistics. Consumer price index all urban consumers. Available at http://www.bls.gov. Accessed 6-12-09
  11. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58:19–36
  12. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ. 1995;310:221–224
  13. Kelton CML, Rebelein RP, Heaton PC, Ferrand Y, Guo JJ. Differences in the cost of antidepressants across state Medicaid programs. J Ment Health Pol Econ. 2008;11(1):33–47
  14. Federal Trade Commission. Generic drug entry prior to patent expiration: an FTC Study. July 2002. Available at, http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf. Accessed 30-04-07.
  15. Gold Standard / Elsevier. Clinical Pharmacology Database. Available by subscription at, http://www.clinicalpharmacology.com. Accessed 6-02-10. Version 2.23, January 2007.
  16. Food and Drug Administration, Division of Drug Marketing Advertising and Communications, U.S. Department of Health and Human Services. Consumer-directed broadcast advertisements, August 1999. Available at, http://www.fda.gov. Accessed 6-02-10.
  17. Henriksson S, Boëthius G, Håkansson J, Isacsson G. Indications for and outcome of antidepressant medication in a general population: a prescription database and medical record study in Jämtland county, Sweden, 1995. Acta Psychiatr Scand. 2003;108:427–432
  18. Torrens M, Fonseca F, Mateu G, Farre M. Efficacy of antidepressants in substance use disorders with and without comorbid depression: a systematic review and meta-analysis. Drug Alcohol Depend. 2005;78:1–22
  19. Centers for Medicare & Medicaid Services. State drug utilization data. Available at, http://www.cms.hhs.gov/MedicaidDrugRebateProgram/SDUD/list.asp#TopOfPage. Accessed 30-11-08.
  20. Box GEP, Jenkins GM. Time Series Analysis: Forecasting and Control. Rev. ed. Oakland, CA: Holden-Day; 1976;
  21. Pankratz A. Forecasting With Dynamic Regression Models. New York, NY: Wiley-Interscience; 1991;
  22. Samuelson WF, Marks SG. Managerial Economics. 5th ed. Hoboken, NJ: Wiley; 2005;
  23. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ Manag Strategy. 1997;Spring:75–90
  24. Kaiser Commission on Medicaid and the Uninsured. Medicaid Outpatient Prescription Drug Benefits: Findings From a National Survey, 2003. Washington, D.C: The Henry J. Kaiser Family Foundation; 2003. Available at, http://www.kff.org. Accessed 6-02-10.
  25. Goetzl D. Glaxo takes bold DTC step for no. 4 depression drug: Wellbutrin's first ads tout lack of sexual side effects. Advertising Age. 1999;October 25:
  26. Advertising Age. Megabrands 2005: top 200 megabrands ranked by total measured U.S. media in 2005. Available at, http://adage.com/datacenter/datapopup.php?article_id = 112524. Accessed 3-11-08.
  27. Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry. 2006;67:972–982
  28. Guo JJ, Kelton CML, Pasquale MK, et al. Price and market-share competition of anti-ulcer gastric medications in the Ohio Medicaid market. Int J Pharm Med. 2004;18(5):271–282
  29. Jing Y, Kelton CML, Guo JJ, Chen Y, Li X, Wigle PR. Price and utilization of HMG Co-A reductase inhibitors (statins) in the US Medicaid program. Drug Benefit Trends. 2006;18(11):580–592
  30. Jing Y, Kelton CML, Guo JJ, Chen Y, Li X, Patel NC. Drug utilization, price, and market-share competition among antipsychotics in US Medicaid programs. Drug Benefit Trends. 2007;19(1):27–41
  31. Jing Y, Klein P, Kelton CML, Li X, Guo JJ. Drug price, utilization, and spending on antiretroviral medication in the U.S. Medicaid programs. AIDS Res Ther. 2007;4(22):Available at http://www.aidsrestherapy.com/content/4/1/228 pages Accessed 18-10-08
  32. Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care. 2004;42:1176–1185
  33. Donohue JM, Berndt ER. Effect of direct-to-consumer advertising on medication choice: the case of antidepressants. J Pub Policy Marketing. 2004;23:115–127
  34. Nagar S, Mehta S, Bhatara V, Aparasu R. Health care consequences of black-box warnings for antidepressants in the United States and Canada. Res Soc Adm Pharm. 2009;published online ahead of print
  35. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164:1356–1363
  36. Pole A, West M, Harrison J. Applied Bayesian Forecasting and Time Series Analysis. London, UK: Chapman and Hall CRC Press; 1994;
  37. Brocklebank JC, Dickey DA. SAS for Forecasting Time Series. 2nd ed.. Cary, NC: SAS Institute Inc; 2003;
  38. Wei WWS. Time Series Analysis, Univariate and Multivariate Methods. 2nd ed.. Boston, MA: Pearson Addison Wesley; 2005;
  39. Box GEP, Tiao GC. Intervention analysis with applications to economic and environmental problems. J Am Stat Assoc. 1975;70:70–79

 Source of funding: none declared.

PII: S1551-7411(10)00002-1

doi: 10.1016/j.sapharm.2009.12.002

Research in Social and Administrative Pharmacy
Volume 7, Issue 1 , Pages 64-80 , March 2011

Article Tools

* Image Usage & Resolution